Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $10.13, for a total transaction of $20,260.00. Following the sale, the president now directly owns 2,827,018 shares of the company's stock, valued at approximately $28,637,692.34. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Songjiang Ma also recently made the following trade(s):
- On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.09, for a total transaction of $24,180.00.
- On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.31, for a total transaction of $24,620.00.
- On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total value of $23,480.00.
- On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total value of $20,280.00.
- On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.25, for a total value of $20,500.00.
- On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total transaction of $23,800.00.
- On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
- On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
- On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
- On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
Gyre Therapeutics Stock Performance
Shares of GYRE stock traded up $0.28 during mid-day trading on Tuesday, reaching $9.49. 290,618 shares of the company were exchanged, compared to its average volume of 82,193. The company has a market capitalization of $888.38 million, a P/E ratio of 189.80 and a beta of 1.93. The business's 50 day simple moving average is $11.29 and its 200 day simple moving average is $12.18. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $19.00.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its earnings results on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The company had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of GYRE. SBI Securities Co. Ltd. bought a new stake in shares of Gyre Therapeutics in the 4th quarter valued at approximately $1,225,000. FMR LLC bought a new stake in Gyre Therapeutics during the third quarter valued at $47,000. Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock valued at $1,425,000 after purchasing an additional 90,557 shares during the last quarter. State Street Corp raised its holdings in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares during the period. Finally, Barclays PLC lifted its position in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after buying an additional 6,855 shares during the last quarter. Institutional investors own 23.99% of the company's stock.
Analyst Ratings Changes
Separately, Noble Financial began coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They set an "outperform" rating for the company.
Read Our Latest Stock Analysis on GYRE
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
